Related Experiment Video
Updated: Mar 21, 2026
Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats
Mehmet Ali Kosekli1, Ugur Sungurtekin, Veli Cobankara
1From the *Gastroenterology Clinic, Hakkari State Hospital, Hakkari, Turkey; †Department of General Surgery, Medical Faculty, and ‡Department of Rheumatology, Medical Faculty, Pamukkale University, Kinikli Campus, Denizli, Turkey; Departments of §Pathology, and ∥Internal Medicine, Faculty of Veterinary Medicine, Mehmet Akif Ersoy University, Istiklal Yerleskesi, Burdur, Turkey; and ¶Department of Gastroenterology, Medical Faculty, Kinikli Campus, Pamukkale University, Denizli, Turkey.
Objectives:
To evaluate the effects of certolizumab, a pegylated monoclonal antibody to tumor necrosis factor α (TNF-α), on experimentally induced acute pancreatitis.
Methods:
Healthy Wistar Albino male rats (n = 36) were randomly divided into 4 groups (9 rats in each group): group 1, control group; group 2, certolizumab group; group 3, cerulein group; and group 4, cerulein + certolizumab group. Acute edematous pancreatitis was induced via intraperitoneal injection of 80-μg/kg cerulein (20 μg/kg, 4 times at 1-hour intervals) in groups 3 and 4. Certolizumab (10 μg) was intraperitoneally administered in groups 2 and 4. Serum levels of amylase, lipase, TNF-α, and lactate dehydrogenase were evaluated. Histopathology and immunohistochemistry of the pancreatic tissue for assessing the activities of malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 were also performed after 72 hours.
Results:
Certolizumab treatment significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.
Conclusion:
This study suggests that certolizumab is a beneficial treatment mode for reducing the severity of acute pancreatitis.
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:30Acute Pancreatitis II: Clinical Manifestations and Management